• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
    • Why Should You Support SAGES?
    • SAGES Swag
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Annual Meeting
      • 2027 Scientific Session Call for Abstracts
      • 2027 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • SAGES Lead Up Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • Innovative Surgical Trends
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Advanced Laparoscopy and Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
    • Foregut Video Atlas
  • Opportunities
    • Join the SAGES Patient Partner Network (PPN)
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs
  • Learning Hub
You are here: Home / Abstracts / Laparoscopic Ileal Interposition (ii) With Diverted Sleeve Gastrectomy (dsg) Is Very Effective for Metabolic Disorders

Laparoscopic Ileal Interposition (ii) With Diverted Sleeve Gastrectomy (dsg) Is Very Effective for Metabolic Disorders

Surendra Ugale, MS, Neeraj Gupta, MBBS, Vishwas Naik, MS, Kd Modi, MD, Sunil Kota, DNB. Kirloskar Hospital and Medwin Hospitals, Hyderabad, Andhra Pradesh, India

 

 

Aim- To evaluate the results of Laparoscopic Ileal Interposition (II) with diverted sleeve gastrectomy (DSG) (II+DSG) for control of type 2 diabetes (T2DM) and related metabolic abnormalities, with weight reduction without causing malabsorption.

Methods- Sixteen (M: F=11:5) patients were selectively subjected to II+DSG, based on their adverse baseline clinical profiles like duration of diabetes > 5-10 years, lower BMIs, poorer basal and stimulated C-peptide response, strong family history of T2DM, requirement of maximum dosages ≥ 3 OHAs and/or Insulin, presence of end organ impairment. Patients had mean age of 50.9 ± 8.3 years (range 34-64 years), duration of diabetes 15.1± 5.8 years (range- 9 to 32 years). All had poorly controlled T2DM (mean HbA1c- 10.1 ± 2.8 %) despite medication. 7 (44%) patients had hypertension, 6 (37%) had dyslipidemia and 6 (37%) had microalbuminuria. The primary outcome was remission of diabetes (HbA1C < 6.5% without OHAs/ Insulin) and secondary outcomes were changes in OHA requirement and components of metabolic syndrome.

Results- Table 1 shows results of II+DSG. Mean follow up was 8.5 ± 5.5 months (range: 1-18 months). Results are in table 1. 11 patients (69 %) had remission in diabetes and others showed significant reduction in medication. 6 patients (85.7 %) had remission in hypertension. There was a significantly declining trend in both lipids and microalbuminuria.

Conclusions- Laparoscopic II+DSG seems to be a very promising procedure for control of Type 2 DM. Amongst the Baraitric operations which are now finding their use in remission of diabetes, Ileal interposition stands alone as a procedure devised specifically for remission of Diabetes. This procedure is especially meant for bringing about remissions in patients with low C-Peptides, Strong family history of diabetes, rapidly increasing insulin requirements, Microalbuminuria and Dyslipidemia. This is achieved without significant issues of nutrient malabsorption , post operative dumping, intractable hypoglycemia and pancreatic exhaustion.

Table 1: Postoperative follow up data of 16 patients. Data expressed as Mean ± SD.

 

Parameter
—————
Months
BMI (kg/m2) FBS(mg%) PLBS(mg%) HbA1C (%) Total Cholest(mg%) LDL-Chol (mg%) HDL-Chol TriGly(mg%) Micralb.(mg/24hr)
Pre-op 28.8± 7.5 243.2 ± 92.5 310.8 ±133.1 10.1±1.9 175. 2±47.3 107± 36.9 40.3 ± 7.9 195.3 ± 87.5 40.2± 23.9
3 mths 23.7± 3.5* 100.6 ±37.8* 156.5 ± 34.6* 7.4± 0.5* 151.6 ± 14.7* 93.5± 15.8* 44.3 ± 2.5* 140.3 ± 13.2* 28.3± 16.8*
6 mths 22.1± 3.8* 147.4 ± 28.4* 136 ±32.4* 6.9± 0.5* 145.5 ± 40.5* 85 ± 35.8 * 42.5 ± 5.2* 98.2 ± 41.3* 32.9± 52.5*
12 mths 21.4± 2.4* 99.4± 17.8* 138.4 ±38.9* 6.5± 0.6* 134.7 ±28.2*

85.6±15.2*

47.7 ±5.9* 85.6 ±15.1* 17.5 ±7.7*
18 mths — 114# 134# 6.4# 180# 94# 46# 130# 10#

 *P < 0.05, statistically significant
# Only single patient has completed 18 mths follow up, so no SD could be calculated


Session Number: Poster – Poster Presentations
Program Number: P506
View Poster

Related



Hours & Info

15821 Ventura Blvd Ste 400
Encino, CA 91436

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2026 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals

Refine Search